[ERBITUX targets metastatic colorectal cancer cells expressing epidermal growth factor receptors (EGFR) on their surface. In Canada, an estimated 19,100 people are diagnosed with colorectal cancer every year. Half of these patients have metastatic disease, or cancer that has spread to other organs, at the time of diagnosis. EGFR is expressed in over 80 per cent of colorectal cancer tumours.] Colorectal cancer is the second leading cause of cancer deaths in Canada. New and potentially life-saving treatments are always welcome, ... We are pleased that ERBITUX is now approved for treatment of metastatic colorectal cancer in Canada.
- Barry Stein
HTML Medium Image Quote Embed:
HTML Large Image Quote Embed:
HTML Text Quote Embed with <blockquote>:
BB Forums Medium Image Quote Embed with <BB Code>:
Please login in order to submit reports.